| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
|
Hepatology
|
2006
|
10.18
|
|
2
|
Maraviroc for previously treated patients with R5 HIV-1 infection.
|
N Engl J Med
|
2008
|
7.31
|
|
3
|
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
|
J Infect Dis
|
2010
|
3.47
|
|
4
|
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
|
N Engl J Med
|
2013
|
3.05
|
|
5
|
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
|
AIDS
|
2010
|
2.51
|
|
6
|
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.
|
J Hepatol
|
2005
|
2.45
|
|
7
|
HIV and syphilis: when to perform a lumbar puncture.
|
Sex Transm Dis
|
2007
|
2.35
|
|
8
|
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
|
PLoS One
|
2009
|
2.23
|
|
9
|
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
|
Lancet Infect Dis
|
2011
|
2.10
|
|
10
|
When should antiretroviral therapy for HIV be started?
|
BMJ
|
2007
|
1.95
|
|
11
|
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
|
J Infect Dis
|
2009
|
1.79
|
|
12
|
Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection.
|
AIDS
|
2006
|
1.57
|
|
13
|
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
|
J Antimicrob Chemother
|
2012
|
1.54
|
|
14
|
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.
|
Cancer
|
2010
|
1.53
|
|
15
|
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
|
AIDS
|
2007
|
1.51
|
|
16
|
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
|
AIDS
|
2003
|
1.43
|
|
17
|
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
|
Cancer
|
2004
|
1.39
|
|
18
|
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.
|
AIDS
|
2012
|
1.38
|
|
19
|
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study).
|
PLoS One
|
2013
|
1.36
|
|
20
|
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
|
Clin Infect Dis
|
2006
|
1.35
|
|
21
|
Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.
|
J Infect Dis
|
2006
|
1.28
|
|
22
|
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
|
AIDS
|
2008
|
1.25
|
|
23
|
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
|
J Infect Dis
|
2003
|
1.25
|
|
24
|
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001.
|
J Acquir Immune Defic Syndr
|
2004
|
1.17
|
|
25
|
Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
|
J Infect Dis
|
2013
|
1.14
|
|
26
|
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
|
J Acquir Immune Defic Syndr
|
2016
|
1.07
|
|
27
|
Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study.
|
Nucl Med Commun
|
2009
|
1.05
|
|
28
|
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
|
Clin Infect Dis
|
2007
|
1.02
|
|
29
|
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
|
AIDS Res Hum Retroviruses
|
2008
|
1.01
|
|
30
|
Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study.
|
J Int AIDS Soc
|
2011
|
0.99
|
|
31
|
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
|
J Acquir Immune Defic Syndr
|
2008
|
0.97
|
|
32
|
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
|
AIDS Res Hum Retroviruses
|
2008
|
0.92
|
|
33
|
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
|
AIDS
|
2005
|
0.92
|
|
34
|
High-risk human papillomavirus infection in HIV-positive African women living in Europe.
|
J Int AIDS Soc
|
2013
|
0.91
|
|
35
|
Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
|
AIDS
|
2013
|
0.91
|
|
36
|
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
|
Antivir Ther
|
2008
|
0.91
|
|
37
|
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).
|
J Acquir Immune Defic Syndr
|
2006
|
0.90
|
|
38
|
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
|
Antivir Ther
|
2006
|
0.90
|
|
39
|
Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load.
|
AIDS
|
2011
|
0.89
|
|
40
|
Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients.
|
AIDS
|
2004
|
0.86
|
|
41
|
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
|
AIDS
|
2014
|
0.86
|
|
42
|
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
|
Antivir Ther
|
2002
|
0.86
|
|
43
|
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
|
AIDS
|
2007
|
0.85
|
|
44
|
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
|
J Acquir Immune Defic Syndr
|
2004
|
0.85
|
|
45
|
Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.
|
J Hepatol
|
2008
|
0.85
|
|
46
|
Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.
|
J Infect Dis
|
2013
|
0.84
|
|
47
|
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.
|
Hum Vaccin Immunother
|
2012
|
0.80
|
|
48
|
Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
|
Basic Clin Pharmacol Toxicol
|
2007
|
0.78
|
|
49
|
A step ahead on the HIV collaboratory.
|
Science
|
2009
|
0.77
|
|
50
|
High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus.
|
AIDS
|
2016
|
0.77
|
|
51
|
Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.
|
HIV Clin Trials
|
2003
|
0.76
|
|
52
|
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
|
J Antimicrob Chemother
|
2010
|
0.76
|
|
53
|
Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
|
J Clin Virol
|
2004
|
0.75
|